Skip to content
HowShorted

TG THERAPEUTICS, INC. short interest in 2018

In 2018, TG THERAPEUTICS, INC.'s disclosed short interest ran from 25.89% of shares outstanding on 12 Jan 2018 to 13.12% on 31 Dec 2018, a change of -12.77 percentage points. The year's high was 27.03% on 31 Jan 2018 and its low 11.92% on 15 Aug 2018, averaging 15.71% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.51 days on 31 May 2018. Full history: TG THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TG THERAPEUTICS, INC. in 2018

2018 in figures

Start of year
25.89% (12 Jan 2018)
End of year
13.12% (31 Dec 2018)
Change
-12.77 pp
High
27.03% (31 Jan 2018)
Low
11.92% (15 Aug 2018)
Average
15.71%
Highest days to cover
16.51 (31 May 2018)
SEC filings marked
8

Every report in 2018

TG THERAPEUTICS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201825.89%10.43
31 Jan 201827.03%13.55
15 Feb 201826.85%8.90
28 Feb 201822.81%9.96
15 Mar 201818.55%9.01results (8-K), 10-K filed
29 Mar 201816.45%9.87
13 Apr 201816.07%10.68
30 Apr 201814.17%12.26
15 May 201813.95%11.18results (8-K), 10-Q filed
31 May 201813.00%16.51
15 Jun 201813.26%7.44
29 Jun 201815.76%8.81
13 Jul 201814.18%15.79
31 Jul 201812.96%7.89
15 Aug 201811.92%11.23results (8-K), 10-Q filed
31 Aug 201812.01%10.41
14 Sep 201812.15%9.19
28 Sep 201812.56%2.70
15 Oct 201812.85%6.48
31 Oct 201813.30%8.72
15 Nov 201813.06%7.9110-Q filed, results (8-K)
30 Nov 201812.83%11.99
14 Dec 201812.37%9.36
31 Dec 201813.12%7.22

See also: TG THERAPEUTICS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.